Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23(9):1147- 57. Abstract

Altundag K et al. Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptornegative breast tumors. Med Hypotheses 2005 Jul 22;[Epub ahead of print] No abstract available

Altundag K et al. Monoclonal antibody-based targeted therapy in breast cancer. Curr Med Chem Anti-Canc Agents 2005;5(2):99-106. Abstract

Ariga R et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;11(4):278-80. Abstract

Bartlett JM. Pharmacodiagnostic testing in breast cancer: Focus on HER2 and trastuzumab therapy. Am J Pharmacogenomics 2005;5(5):303- 15. Abstract

Baselga J et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23(10):2162-71. Abstract

Benohr P et al. Her-2/neu expression in breast cancer — A comparison of different diagnostic methods. Anticancer Res 2005;25(3B):1895-900. Abstract

Buzdar AU et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23(16):3676-85. Abstract

De Laurentiis M et al. Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology. Ann Oncol 2005;16(Suppl 4):iv7-iv13. Abstract

Del Mastro L et al. HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer 2005;93(1):7-14. Abstract

DiGiovanna MP et al. Relationship of epidermal growth factor receptor expression to ErbB- 2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005;23(6):1152-60. Abstract

Dobson R. Trastuzumab halves risk of recurrence of breast cancer in some women. BMJ 2005;331(7523):986. No abstract available

Dressler LG et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23(19):4287-97. Abstract

Dybdal N et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005;93(1):3-11. Abstract

Ellis CM et al. HER2 amplification status in breast cancer: A comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol 2005;58(7):710-4. Abstract

Ewer MS et al. Reversibility of trastuzumabrelated cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6. Abstract

Gasparini G et al. Therapy of breast cancer with molecular targeting agents. Ann Oncol 2005;16 Suppl 4:iv28-iv36. Abstract

Gong Y et al. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: Comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol 2005;18(8):1015-21. Abstract

Hampton T. Monoclonal antibody therapies shine in breast cancer clinical trials. JAMA 2005;293(24):2985-9. No abstract available

Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: A technical review with interpretive guidelines. Hum Pathol 2005;36(3):250-61. Abstract

Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control 2005;12(2):73-81. Abstract

Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353(16):1734-6. No abstract available

Kounelis S et al. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: Comparison with immunohistochemistry. Anticancer Res 2005;25(2A):939-46. Abstract

Lan C et al. erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. Am J Clin Pathol 2005;124(1):97-102. Abstract

Leyland-Jones B et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21(21):3965-71. Abstract

Lottner C et al. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 2005;205(5):577-84. Abstract

Ma Y et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: Effect on daily practice. Clin Cancer Res 2005;11(12):4393-9. Abstract

Mass RD et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6(3):240-6. Abstract

Nabholtz JM, Gligorov J. Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. Expert Opin Pharmacother 2005;6(9):1555- 64. Abstract

Pegram MD et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96(10):739-49. Abstract

Peoples GE et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005;23(30):7536-45. Abstract

Perez EA et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. Proc ASCO 2005;Abstract 556.

Perez EA et al. NCCTG N9831: May 2005 update. Presentation. ASCO 2005;Abstract 556.

Perez EA et al. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. Proc ASCO 2004;Abstract 567.

Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22(2):322-9. Abstract

Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005. No abstract available

Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract

Press MF et al. Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11(18):6598-607. Abstract

Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer combined analysis of NSABP-B31/ NCCTG-N9831. Presentation. ASCO 2005. No abstract available

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673- 84. Abstract

Rueckert S et al. A monoclonal antibody as an effective therapeutic agent in breast cancer: Trastuzumab. Expert Opin Biol Ther 2005;5(6):853-66. Abstract

Schmidt M et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 2005;7(2):R256-66. Abstract

Seidman A et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215-21. Abstract

Spector N et al. The ErbB2 pathway in breast cancer: Best approaches for maximum efficacy. Breast Cancer Res Treat 2004;Abstract MS3-4.

Spicer J et al. Adjuvant trastuzumab for HER2-positive breast cancer. Lancet 2005;366(9486):634. No abstract available

Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract

Tripathy D. Targeted therapies in breast cancer. Breast J 2005;11(Suppl 1):30-5. Abstract

Wakeling AE. Inhibitors of growth factor signalling. Endocr Relat Cancer 2005;12 Suppl 1:S183-7. Abstract

Willems A et al. Antibody therapy for breast cancer. Anticancer Res 2005;25(3A):1483-9. Abstract

Yamaguchi Y et al. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab. Anticancer Res 2005;25(2A):827-32. Abstract